移动-智能医疗管理系统在痛风患者管理中的应用效果  

Clinical application of mobile-intelligent medical management system for gout patients

作　　者：冯秀南 张凤晓 李铁[1] 王馨[1] 赵令[1] 石晓东[1] Feng Xiunan;Zhang Fengxiao;Li Tie;Wang XinZhao Ling;Shi Xiaodong(Department of Rheumatology,the First Hospital of Jilin University,Changchun130021,China)

机构地区：[1]吉林大学第一医院风湿免疫科,长春130021

出　　处：《中华全科医师杂志》2025年第1期76-81,共6页Chinese Journal of General Practitioners

基　　金：吉林省科技厅自然科学基金(YDZJ202201ZYTS132)。

摘　　要：目的探讨移动-智能医疗管理系统在痛风患者临床应用中的疗效。方法该研究为随机对照研究。选取2022年1月至2023年10月在吉林大学第一医院风湿免疫科门诊就诊的102例首次诊断的痛风患者作为研究对象, 按随机数字表法分为试验组53例和对照组49例。试验组患者采用M-G健康(mobil-gout health)管理系统随访, 定期(每周)检测指尖尿酸, 针对尿酸情况, 系统给予反馈治疗信息, 以及医生每2周在APP上及时给予药物、饮食等指导的人工反馈信息。对照组仍保持传统的门诊就诊模式。所有痛风患者均在入组当天和第3、6个月给予血尿酸水平、肝肾功能等生化指标检测和体格检查, 评估痛风发作受累关节数和发作频次, 采用视觉模拟量表(VAS)进行疼痛评分, 并进行两组各项指标的统计分析比较。结果随访第3、6个月时两组比较, 试验组尿酸水平[408.0(345.0, 450.0)、371.0(338.5, 409.0)μmol/L]和VAS评分[(6.66±1.46)、(4.68±1.80)分]明显低于对照组[458.0(409.0, 482.0)、412.0(368.5, 445.0)μmol/L, (7.45±1.06)、(5.88±1.52)分], 差异均有统计学意义(Z=3.37、4.61, t=14.12、13.72, 均P<0.01)。随着随访期的延长, 试验组痛风发作时的平均受累关节数较对照组有所下降, 痛风发作频次也较对照组下降, 但差异无统计学意义(P>0.05)。在随访的第6个月时, 试验组的痛风发作频次明显低于对照组(χ^(2)=9.30, P<0.05)。结论基于智能手机的管理痛风的M-G健康管理系统有助于痛风患者的尿酸控制及疾病复发。Objective To explore the clinical application of mobile-intelligent medical management system for gout patients.MethodsThis study was a randomized controlled trial.One hundred and two patients with gout who visited rheumatology department of the First Hospital of Jilin University from January 2022 to October 2023 were randomly divided into study group(n=53)and the control group(n=49).Patients in the study group were managed by the mobil-gout(M-G)health management system which consists of a distant management plateform and an App.The body weight and blood uric acid levels were regularly self-tested by patients,and the information was sent to the system,the doctor gave feed-back advice on medication adjustment and dietary management every 2 weeks.While patients in the control group were managed following the conventional outpatient consultation mode.The serum uric acid levels,liver and kidney function tests and physical examinations were conducted on the day of enrollment and 3 and 6 months after treatment.The number of affected joints and the frequency of attacks were evaluated,and pain was assessed using the visual analog scale(VAS).The efficacy of treatment were compared between two groups.ResultsAfter 3 and 6 months of treatment,the serum uric acid levels in study group were significantly lower than those in control group(408.0(345.0,450.0)μmol/L vs.458.0(409.0,482.0)μmol/L,371.0(338.5,409.0)μmol/L vs.412.0(368.5,445.0)μmol/L;Z=3.37,4.61,P<0.01);and VAS scores were also significantly lower than those in control group(6.66±1.46 vs.4.68±1.80,7.45±1.06 vs.5.88±1.52;t=14.12,13.72,P<0.01).After 6 months of treatment,the frequency of gout attacks in the study group was significantly lower than that in the control group(χ^(2)=9.30,P<0.05).As the follow-up period was extended,the average number of joints affected by gout attacks and the frequency of gout attacks in the study group showed a reducing trend compared to the control group,but the differences were not statistically significant(P>0.05).ConclusionsThe

关 键 词：痛风 移动医疗 健康管理 

分 类 号：R589.7[医药卫生—内分泌]